首页> 外文期刊>Bone marrow transplantation >Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study.
【24h】

Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study.

机译:来自无关亲戚的外周血干细胞移植的可行性和安全性:单中心研究的结果。

获取原文
获取原文并翻译 | 示例
       

摘要

We compared the outcomes in patients receiving unrelated peripheral blood stem cell transplants (PBSCT) with those receiving bone marrow transplants (BMT) in a matched pair analysis. Seventy-four patients with hematological malignancies with HLA-matched (77%) and mismatched (23%) donors were analyzed in this study. Thirty-four patients (45%) were considered as high risk patients. Sixty-eight patients received standard conditioning regimens with Bu/Cy or TBI/Cy. Six patients received an intensified conditioning regimen with the addition of etoposide, thiotepa or melphalan. GVHD prophylaxis consisted of prednisolone, cyclosporine and methotrexate. Groups were matched for patient, donor, transplant characteristics and HLA compatibility. Peripheral blood stem cell collection led to the collection of a higher number of CD34+ and CD3+ cells in comparison to bone marrow collection. Leukocyte engraftment in the PBSCT group occurred in 14 days (median; range 6-26 days) and in the BMT group in 19 days (range 9-29 days; P < 0.02). The time of platelet engraftment did not differ significantly. The incidence of grades II-lV acute GVHD in the group of HLA-identical patients was 35% in the PBSCT group and 25% in the BMT group (P < 0.33, log-rank). However, there was a significant difference (P < 0.05, log-rank) in incidence and time to onset of acute GVHD II-IV comparing all patients, including the 17 mismatched transplants. Disease-free survival was 51% (19 patients) with a median of 352 days and 59% (21 patients) with a median of 760 days for PBSC and BMT transplants, respectively. In conclusion, our results indicate that allogeneic PBSCT led to significantly faster leukocyte engraftment but is associated with a higher incidence and more rapid onset of severe acute GVHD comparing all patients, including the 17 mismatched transplants. However, the incidence of severe acute GVHD in HLA-identical patients was not different between the PBSCT and BMT groups.
机译:在配对分析中,我们比较了接受无关的外周血干细胞移植(PBSCT)和接受骨髓移植(BMT)的患者的结局。在这项研究中分析了74名HLA匹配(77%)和不匹配(23%)供者的血液系统恶性肿瘤患者。三十四名患者(45%)被认为是高危患者。 68名患者接受了Bu / Cy或TBI / Cy的标准调理方案。六名患者接受了增强的调理方案,并添加了依托泊苷,硫替特帕或美法仑。预防GVHD包括泼尼松龙,环孢素和甲氨蝶呤。根据患者,供体,移植特征和HLA相容性对各组进行匹配。与骨髓收集相比,外周血干细胞收集导致收集更多数量的CD34 +和CD3 +细胞。 PBSCT组中的白细胞植入发生在14天(中位数;范围为6-26天)中,而BMT组中的白细胞植入发生在19天中(范围为9-29天; P <0.02)。血小板植入时间无明显差异。与HLA相同的患者组中II-IV级急性GVHD的发生率在PBSCT组中为35%,在BMT组中为25%(P <0.33,对数秩)。但是,与包括17例错配移植物在内的所有患者相比,急性GVHD II-IV的发病率和发病时间有显着差异(P <0.05,对数秩)。 PBSC和BMT移植的无病生存率分别为51%(19名患者)和760天,中位数为352天和59%(21名患者)和中位数为760天。总之,我们的结果表明,同种异体PBSCT与所有患者(包括17例错配的移植患者)相比,严重急性GVHD的发生率显着提高,但与严重急性GVHD的发生率更高,起病更快有关。但是,PBSCT组和BMT组之间在HLA相同的患者中严重急性GVHD的发生率没有差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号